Prognostic value of CURB-65 and pneumonia severity index (PSI) in COVID-19 pneumonia: A retrospective cohort study

Abstract

Objective: To validate a better scoring system between CURB-65 and the pneumonia severity index (PSI) to predict the need for intensive care unit admission and 30-day mortality in patients with COVID-19 pneumonia. Methods: A retrospective cohort study was conducted on patients in a tertiary care hospital in Kota, Rajasthan. Relevant data about history, and general and systemic examination with laboratory investigations was collected. Patients were categorized into different risk groups for ICU admission and 30-day mortality according to CURB-65 and PSI. Sensitivity, specificity, positive predictive value, negative predictive value, and area under the curve were calculated. Continuous variables, means and percentages were compared using the t-test for numerical data and the Chi-square test for nominal data. Results: 100 patients who tested positive for SARS-CoV-2 by RT-PCR were included; 67 were male and 33 were female. 58 patients had severe disease (SpO₂≤90%) and 30 patients died. CURB-65 had an area under the curve (AUC) of 0.81 for predicting ICU admission, with a sensitivity of 92% and a specificity of 54% for high risk patients. Meanwhile, PSI had an AUC of 0.88, with a sensitivity of 83% and a specificity of 73% in high risk patients. In addition, CURB-65 had an AUC of 0.79 for predicting 30-day mortality, with a sensitivity of 60% and a specificity of 89% in high risk patients. PSI had an AUC of 0.71 for predicting 30-day mortality, with a sensitivity of 90% and a specificity of 46% in high risk patients. Conclusions: This single-centre retrospective study involving a cohort of COVID-19 patients demonstrates that CURB-65 and PSI are powerful tools for predicting mortality. However, PSI appears to be slightly better at predicting the need for intensive care unit admission in high-risk patients.

Keywords

COVID-19 / CURB-65 / Pneumonia severity index / Pneumonia / Mortality

References

[1] Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID—19. Sci Rep 2021; 11(1): 4263.

[2] Elmoheen A, Abdelhafez I, Salem W, Bahgat M, Elkandow A, Tarig A, et al. External validation and recalibration of the CURB—65 and PSI for predicting 30—day mortality and critical care intervention in multiethnic patients with COVID—19. Int J Infect Dis 2021; 111: 108-116.

[3] García Clemente MM, Herrero Huertas J, Fernández Fernández A, De La Escosura Muñoz C, Enríquez Rodríguez AI, Pérez Martínez L, et al. Assessment of risk scores in COVID—19. Int J Clin Pract 2021; 75(12): e13705.

[4] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID—19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239.

[5] Marchandot B, Sattler L, Jesel L, Matsushita K, Schini—Kerth V, Grunebaum L, et al. COVID—19 related coagulopathy: A distinct entity? J Clin Med 2020; 9(6): 1651.

[6] Eldaboosy AM, Halima KM, Shaarawy AT, Kanany HM, Elgamal EM, El—Gendi A, et al. Comparison between CURB—65, PSI, and SIPF scores as predictors of ICU admission and mortality in community—acquired pneumonia. Egypt J Crit Care Med 2015; 3: 37-44.

[7] Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006; 61(5): 419-424.

[8] Nguyen Y, Corre F, Honsel V, Curac S, Zarrouk V, Burtz CP, et al. A nomogram to predict the risk of unfavourable outcome in COVID—19: A retrospective cohort of 279 hospitalized patients in Paris area. Ann Med 2020; 52(7): 367-375.

[9] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID—19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395(10229): 1054-1062.

[10] Liu K, Chen Y, Lin R, Han K. Clinical features of COVID—19 in elderly patients: A comparison with young and middle—aged patients. J Infect 2020; 80(6): e14-e18.

[11] Satici C, Demirkol MA, Sargin Altunok E, Gursoy B, Alkan M, Kamat S, et al. Performance of pneumonia severity index and CURB—65 in predicting 30—day mortality in patients with COVID—19. Int J Infect Dis 2020; 98: 84-89.

[12] Chalmers JD, Julia R. Can we use severity assessment tools to increase outpatient management of community—acquired pneumonia? Eur J Intern Med 2012; 23(5): 398-406.

[13] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID—19. J Infect 2020; 80(6): 607-613.

[14] Chaomin W, Xiaoyan C, Yanping C, Jia’an X, Xing Z, Sha X, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. J Emerg Med 2020; 180(7): 934-943.

[15] Fei Z, Ting Y, Ronghui D, Guohui F, Ying L, Zhibo L, et al. Clinical course and risk factors for mortality of adult inpatients with COVID—19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395(10229): 1054-1062.

[16] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical and mortal COVID—19 cases: A systematic literature review and meta—analysis. J Infect 2020; 81(2): e16-e25.